A 62-year-old man with diabetes mellitus presents with fever, dysuria, and flank pain. Urine culture grows a gram-negative rod. The organism is resistant to ceftriaxone and cefotaxime but susceptible to carbapenems. Which investigation is most appropriate to confirm the suspected mechanism of resistance?

## Diagnosis of ESBL Resistance **Key Point:** The clinical presentation (UTI with fever, flank pain in a diabetic patient) and resistance pattern (resistant to 3rd-generation cephalosporins such as ceftriaxone and cefotaxime, yet **susceptible to carbapenems**) is classic for ESBL-producing gram-negative bacteria. Carbapenem susceptibility effectively rules out carbapenemase production. ### Investigation of Choice: Double-Disk Synergy Test (DDST) The **DDST with clavulanic acid** is the gold standard confirmatory test for ESBL production: 1. **Principle:** Clavulanic acid is a β-lactamase inhibitor. If the organism produces an ESBL, clavulanic acid will inhibit the enzyme and restore susceptibility to the cephalosporin — demonstrated as an enhanced zone of inhibition. 2. **Technique:** A ceftriaxone or cefotaxime disk and an amoxicillin-clavulanic acid disk are placed 15–20 mm apart on Mueller-Hinton agar inoculated with the test organism. 3. **Positive Result:** An enhanced ("keyhole" or "D-shaped") zone of inhibition around the cephalosporin disk toward the clavulanic acid disk confirms ESBL production. 4. **Sensitivity & Specificity:** ~90–95% for ESBL detection. **High-Yield:** DDST is the most widely used, cost-effective, and clinically validated method in resource-limited settings (including India) for ESBL confirmation, as per CLSI and EUCAST guidelines. ### Why DDST is Preferred Over Other Tests | Test | Purpose | Why NOT appropriate here | |------|---------|--------------------------| | **DDST** | Confirms ESBL (β-lactamase inhibitor-sensitive) | ✅ Correct choice | | **Modified Hodge Test (MHT)** | Detects **carbapenemase** production | The organism is **carbapenem-susceptible**, so MHT would be **negative** and is irrelevant here; MHT is used when carbapenem resistance is suspected | | **E-test MIC** | Quantifies antibiotic susceptibility | Does not identify the mechanism of resistance; it is a susceptibility tool, not a confirmatory mechanistic test | | **Chromogenic cephalosporin substrate** | Detects β-lactamase activity (non-specific) | Cannot distinguish ESBL from AmpC or other β-lactamases; not confirmatory for ESBL | **Clinical Pearl:** The fact that the organism is **susceptible to carbapenems** is the critical clue — it rules out carbapenemase (KPC, NDM, OXA-48, etc.) and points directly to ESBL as the mechanism. The Modified Hodge Test (option A) would be expected to be **negative** in this scenario, making it an inappropriate confirmatory test. DDST specifically exploits the inhibitor-sensitivity of ESBLs to confirm their presence. **Mnemonic:** **DDST = Diagnostic Disk Synergy Test** — the "synergy" between clavulanic acid and the cephalosporin disk confirms ESBL. [cite: Koneman's Color Atlas and Textbook of Diagnostic Microbiology, 6th ed., Ch. 9; CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing]